Pfizer has agreed to pay $59.7m to resolve illegal payments to healthcare professionals made by Biohaven Pharmaceuticals, a biopharma it acquired over two years ago. The charges allege that ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired ... will use every tool at its disposal to prevent pharmaceutical manufacturers from undermining the objectivity ...

(RTTNews) - Biohaven Pharmaceuticals (BHVN), on Tuesday announced that the FDA has accepted its New Drug Application for Troriluzole for the treatment of adult patients with spinocerebellar ataxia ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a price target of $54.00 on Biohaven Pharmaceutical (TADAWUL:2070) ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... Wedbush analyst Laura Chico maintained a Buy rating on Biohaven ...